Mobile website
Archive > Volume 20 Issue 2 > 2013,20(2):217-224. DOI:10.3872/j.issn.1007-385X.2013.02.016 Prev Next
Clinical Research
Efficacy of dendritic cells/cytokine induced killer cells adoptive immunotherapy combined with chemotherapy in treatment of metastatic colorectal cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To evaluate the therapeutic effect and safety of dendritic cells-cytokine induced killer cells (DC-CIK) combined with chemotherapy in the treatment of metastatic colorectal cancer (mCRC). Methods: 80 mCRC patients were selected from Dalian Centre Hospital during November 2010 to November 2011. 40 patients were treated by DC-CIK combined with chemotherapy (combined group), and another 40 patients were treated by chemotherapy alone (chemotherapy group). The immune function, therapeutic effect, toxicity and quality of life (QOL) were compared between the two groups after the treatment. Results: 160 cycles of DC-CIK were successfully treated. There were no obvious changes of T cell subsets in the peripheral blood in the combined group (P>0.05), while the ratios of CD3+, CD3+CD4+, CD3+ CD8+ and CD3-CD56+ cells were significantly decreased after the treatment in the chemotherapy group, and obviously lower than that in the combined group (P<0.05). After treatment for 3 cycles, the IFN-γ level of CD4+ T cells in the combined group was significantly increased (P<0.05), while the levels of IFN-γ, IL-2 and TNF-α in the chemotherapy group were significantly decreased after the treatment and were obviously lower than that in the combined group (P<005). No significant differences were found in the overall response rate (RR) between the combined group and the chemotherapy group (37.5% vs 22.5%,P>0.05). The disease control rate (DCR) of the combined group was significantly higher than that of the chemotherapy group (77.5% vs 50.0%, P<0.05). Ⅲ-Ⅳ grade leucopenia and tardily diarrhea in the combined group were obviously lower than those of the chemotherapy group (17.5% vs 42.5%, 50% vs 25.0%, P<0.05). Other side effects showed no significant differences between the two groups, which can be alleviated after symptomatic treatment (P>0.05). The median progression-free survival (PFS) of the combined group was longer than that of the chemotherapy group (6.5 months vs 4.5 months, P<0.05), while the median overall survival (OS) of the two groups had no significant difference (P>0.05). The physical and emotional functions of the combined group were better than those of the chemotherapy group (P<0.05). Conclusion: Treatment with DC-CIK adoptive immunotherapy combined with chemotherapy can effectively improve the immune function, improve the efficacy, reduce the side effects of chemotherapy, prolong the PFS, and improve QOL of mCRC patients.
Keywords:
Project Supported:
Clc Number:
